Compound Evidence File
#EC-2026-0053
SLU-PP-332 250mcg + BAM15 50mcg Blend
Filed under Oral Tablets. The bureau holds 133 laboratory returns for this compound from 49 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
49 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 10.0 | 10.0 | 28 Feb 2026 | 9 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 17 May 2026 | 14 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Jan 2026 | 2 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Mar 2026 | 24 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Dec 2025 | 3 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 14 Apr 2026 | 27 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 11 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 27 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Apr 2026 | 6 Aug 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Jun 2026 | 1 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Dec 2025 | 17 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 9.9 | 12 Apr 2026 | 4 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 | 3 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 13 Jun 2026 | 14 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Jan 2026 | 25 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 1 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Dec 2025 | 4 May 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 27 Mar 2026 | 24 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 6 May 2026 | 12 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 4 Apr 2026 | 15 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 26 May 2026 | 8 Jul 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 9.9 | 9.9 | 9.9 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 9.5 | 9.0 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.8 | 7.1 | 9.6 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.7 | 7.4 | 10.0 | 21 May 2026 | 21 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 8.7 | 8.7 | 8.7 | 13 Jun 2025 | 13 Jun 2025 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 8.7 | 8.7 | 8.7 | 20 Jun 2025 | 20 Jun 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 8.7 | 8.7 | 8.7 | 8 Jul 2025 | 8 Jul 2025 |
| Peptide SciencesCASE #VI-2026-0867 | X | 8 | 8.6 | 6.3 | 10.0 | 3 Jul 2025 | 17 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.5 | 6.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | X | 2 | 8.3 | 7.9 | 8.7 | 14 Jan 2025 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 7.6 | 7.2 | 8.0 | 24 May 2026 | 24 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 2 | 7.5 | 6.5 | 8.6 | 13 Jun 2025 | 20 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 7.0 | 5.9 | 8.1 | 24 Apr 2025 | 24 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 6.9 | 6.9 | 6.9 | 25 Apr 2025 | 25 Apr 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 1 | 6.9 | 6.9 | 6.9 | 13 Feb 2025 | 13 Feb 2025 |
| Atomik LabzCASE #VI-2026-0327 | X | 3 | 6.6 | 4.1 | 7.9 | 8 Jul 2025 | 17 May 2026 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 6.4 | 6.4 | 6.4 | 6 May 2025 | 6 May 2025 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 6.2 | 6.2 | 6.2 | 13 Feb 2025 | 13 Feb 2025 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 3 | 6.0 | 5.5 | 6.5 | 9 Jun 2025 | 21 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 3 | 4.9 | 3.1 | 6.7 | 2 Jul 2025 | 17 May 2026 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 4.4 | 4.4 | 4.4 | 8 Jul 2025 | 8 Jul 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 2.8 | 2.8 | 2.8 | 21 May 2025 | 21 May 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 1.8 | 1.8 | 1.8 | 17 Dec 2024 | 17 Dec 2024 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 0.4 | 0.4 | 0.4 | 20 Jun 2025 | 20 Jun 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 20 Jun 2025 | 20 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 20 Jun 2025 | 20 Jun 2025 |
Open any subject to view the batch-level evidence for SLU-PP-332 250mcg + BAM15 50mcg Blend alone.